{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:48:33Z","timestamp":1785422913905,"version":"3.56.0"},"reference-count":76,"publisher":"Cambridge University Press (CUP)","issue":"8","license":[{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1047951117000609_abs1\" sec-type=\"general\"><jats:title>Background<\/jats:title><jats:p>Palivizumab is the standard immunoprophylaxis against serious disease due to respiratory syncytial virus infection. Current evidence-based prophylaxis guidelines may not address certain children with CHD within specific high-risk groups or clinical\/management settings.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951117000609_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>An international steering committee of clinicians with expertise in paediatric heart disease identified key questions concerning palivizumab administration; in collaboration with an additional international expert faculty, evidence-based recommendations were formulated using a quasi-Delphi consensus methodology.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951117000609_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Palivizumab prophylaxis was recommended for children with the following conditions: &lt;2 years with unoperated haemodynamically significant CHD, who are cyanotic, who have pulmonary hypertension, or symptomatic airway abnormalities; &lt;1 year with cardiomyopathies requiring treatment; in the 1st year of life with surgically operated CHD with haemodynamically significant residual problems or aged 1\u20132 years up to 6 months postoperatively; and on heart transplant waiting lists or in their 1st year after heart transplant. Unanimous consensus was not reached for use of immunoprophylaxis in children with asymptomatic CHD and other co-morbid factors such as arrhythmias, Down syndrome, or immunodeficiency, or during a nosocomial outbreak. Challenges to effective immunoprophylaxis included the following: multidisciplinary variations in identifying candidates with CHD and prophylaxis compliance; limited awareness of severe disease risks\/burden; and limited knowledge of respiratory syncytial virus seasonal patterns in subtropical\/tropical regions.<\/jats:p><\/jats:sec><jats:sec id=\"S1047951117000609_abs4\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>Evidence-based immunoprophylaxis recommendations were formulated for subgroups of children with CHD, but more data are needed to guide use in tropical\/subtropical countries and in children with certain co-morbidities.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1047951117000609","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T07:53:02Z","timestamp":1497599582000},"page":"1504-1521","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":23,"title":["CHD and respiratory syncytial virus: global expert exchange recommendations"],"prefix":"10.1017","volume":"27","author":[{"given":"Robert M. R.","family":"Tulloh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constancio","family":"Medrano-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Checchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokata","family":"Sumitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gorenflo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun","family":"Jung Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Juanico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Gil-Jaurena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hwan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Farha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dodge-Khatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Notario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Wegzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"key":"S1047951117000609_ref16","first-page":"19","volume-title":"Recommendations for Prevention of RSV Infection in Taiwan","year":"2015"},{"key":"S1047951117000609_ref61","unstructured":"Instituto Nacional de Salud. Boletin epidemiologico. Retrieved April 22, 2016, fromhttp:\/\/www.ins.gov.co\/boletin-epidemiologico\/Paginas\/default.aspx."},{"key":"S1047951117000609_ref18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1665"},{"key":"S1047951117000609_ref73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04335.x"},{"key":"S1047951117000609_ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-009-9549-4"},{"key":"S1047951117000609_ref68","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268898008905"},{"key":"S1047951117000609_ref1","first-page":"609","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"Pickering","year":"2012"},{"key":"S1047951117000609_ref57","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S5696"},{"key":"S1047951117000609_ref52","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199909000-00042"},{"key":"S1047951117000609_ref12","first-page":"61","article-title":"RSV prophylaxis with palivizumab in high-risk children \u2013 update German national guidelines 2008","volume":"157","author":"Liese","year":"2009","journal-title":"Monatsschr Kinderheilkd"},{"key":"S1047951117000609_ref29","unstructured":"Korean Ministry of Health & Welfare. Reimbursement guidelines. Data on file, 2012."},{"key":"S1047951117000609_ref15","first-page":"432.e1","volume-title":"An Pediatr (Barc)","volume":"72","author":"Medrano Lopez","year":"2010"},{"key":"S1047951117000609_ref70","doi-asserted-by":"publisher","DOI":"10.1017\/S095026880600776X"},{"key":"S1047951117000609_ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000329"},{"key":"S1047951117000609_ref74","doi-asserted-by":"crossref","unstructured":"Friedman D , Wong P , Fryzek J , et al. Respiratory syncytial virus hospitalization risk in the second year of life by condition in children with congenital heart disease. Pediatric Academic Societies Annual Meeting, April 30 to May 3, 2016, Baltimore.","DOI":"10.1371\/journal.pone.0172512"},{"key":"S1047951117000609_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.11.058"},{"key":"S1047951117000609_ref53","first-page":"284","article-title":"Prophylaxis in RSV infection (palivizumab) \u2013 is it worthwhile?","volume":"93","author":"Hashmi","year":"2000","journal-title":"Ir Med J"},{"key":"S1047951117000609_ref35","author":"Leslie"},{"key":"S1047951117000609_ref45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir928"},{"key":"S1047951117000609_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"S1047951117000609_ref28","first-page":"19","article-title":"Palivizumab use among children with congenital heart disease in Quebec: impact of Canadian guidelines on clinical practice","volume":"11","author":"Bellavance","year":"2006","journal-title":"Paediatr Child Health"},{"key":"S1047951117000609_ref49","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1333"},{"key":"S1047951117000609_ref36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2011.02219.x"},{"key":"S1047951117000609_ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2014.05.030"},{"key":"S1047951117000609_ref9","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00454-2"},{"key":"S1047951117000609_ref19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.6.1442"},{"key":"S1047951117000609_ref24","doi-asserted-by":"publisher","DOI":"10.3310\/hta15050"},{"key":"S1047951117000609_ref6","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2011.54.5.192"},{"key":"S1047951117000609_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2004.06.007"},{"key":"S1047951117000609_ref76","unstructured":"Scaparrotta A , Attanasi M , Di Pillo S , Chiarelli F . Pediatric lower respiratory infections. OMICS Group. Retrieved October 22, 2016, from http:\/\/www.esciencecentral.org\/ebooks\/pediatric-lower\/pdf\/Pediatric-Lower-respiratory-infections.pdf."},{"key":"S1047951117000609_ref34","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.143057"},{"key":"S1047951117000609_ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5245(04)00064-1"},{"key":"S1047951117000609_ref60","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12553"},{"key":"S1047951117000609_ref66","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200911020-00003"},{"key":"S1047951117000609_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2014.05.001"},{"key":"S1047951117000609_ref64","doi-asserted-by":"publisher","DOI":"10.1111\/apa.13061"},{"key":"S1047951117000609_ref8","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.110531"},{"key":"S1047951117000609_ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/646780"},{"key":"S1047951117000609_ref21","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951105000569"},{"key":"S1047951117000609_ref65","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit512"},{"key":"S1047951117000609_ref23","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.734886"},{"key":"S1047951117000609_ref25","doi-asserted-by":"publisher","DOI":"10.3310\/hta12360"},{"key":"S1047951117000609_ref48","first-page":"465","article-title":"Mortality and morbidity of respiratory syncytial virus bronchiolitis in congenital heart disease patients 1999-2012 \u2013 a population-based study","volume":"9","author":"Tsang","year":"2014","journal-title":"Congenit Heart Dis"},{"key":"S1047951117000609_ref40","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12111"},{"key":"S1047951117000609_ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2008.01017.x"},{"key":"S1047951117000609_ref59","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e32835dce2f"},{"key":"S1047951117000609_ref43","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181343b7e"},{"key":"S1047951117000609_ref10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.6.321","article-title":"Preventing hospitalizations for respiratory syncytial virus infection","volume":"20","author":"Robinson","year":"2015","journal-title":"Paediatr Child Health"},{"key":"S1047951117000609_ref55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2012.01744.x"},{"key":"S1047951117000609_ref72","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2011.212563.80"},{"key":"S1047951117000609_ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-015-0203-x"},{"key":"S1047951117000609_ref27","unstructured":"Howick J, Chalmers I, Glasziou P, et al. \u2018The Oxford Levels of Evidence 2\u2019. Oxford Centre for Evidence-Based Medicine, 2011. Retrieved September 1, 2016, from http:\/\/www.cebm.net\/index.aspx?o=5653."},{"key":"S1047951117000609_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(94)70116-4"},{"key":"S1047951117000609_ref17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1017\/S1047951103000891","article-title":"Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease","volume":"13","author":"Tulloh","year":"2003","journal-title":"Cardiol Young"},{"key":"S1047951117000609_ref39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-305"},{"key":"S1047951117000609_ref54","doi-asserted-by":"publisher","DOI":"10.1111\/apa.12658"},{"key":"S1047951117000609_ref50","first-page":"119","article-title":"Children with hemodynamically significant congenital heart disease can be identified through population-based registers","volume":"7","author":"Bergman","year":"2015","journal-title":"Clin Epidemiol"},{"key":"S1047951117000609_ref7","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000108220.94201.1a"},{"key":"S1047951117000609_ref51","doi-asserted-by":"publisher","DOI":"10.1157\/13124223"},{"key":"S1047951117000609_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.2006.02179.x"},{"key":"S1047951117000609_ref30","unstructured":"German Society for Paediatric Infectious Diseases (DGPI), German Society of Pediatric Cardiology (DGPK), Society of Pediatric Pneumology (GPP), Society of Neonatology and Pediatric Intensive Care Medicine (GNPI) and Professional Association of Child and Adolescent Physicians (BVKJ). [Guideline for the prevention of serious illnesses by respiratory syncytial virus in children at risk]. Retrieved June 2, 2016, from http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/048-012l_S2k_Prophylaxe_von_schweren_RSV-Erkrankungen_bei_Risikokindern_07-2012-12-2016.pdf."},{"key":"S1047951117000609_ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198208123070702"},{"key":"S1047951117000609_ref63","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(11)60057-0"},{"key":"S1047951117000609_ref20","first-page":"1","article-title":"The Delphi technique: making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Pract Assess Res Eval"},{"key":"S1047951117000609_ref67","first-page":"38","article-title":"Respiratory infections, Down\u2019s syndrome and congenital heart disease: the CIVIC 21 study","volume":"71","author":"Medrano Lopez","year":"2009","journal-title":"An Pediatr (Barc)"},{"key":"S1047951117000609_ref71","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000108191.13799.09"},{"key":"S1047951117000609_ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-004-4539-6"},{"key":"S1047951117000609_ref75","doi-asserted-by":"crossref","unstructured":"Wang D , Li A , Paes B , Mitchell I , Lanct\u00f4t K . Comparison of first- and second-season palivizumab prophylaxis in patients with congenital airway anomalies (CAA) in the CARESS database (2005\u20132015). International Society for Pharmacoeconomics and Outcomes Research 21st Annual International Meeting, May 21\u201325, 2016, Washington, DC.","DOI":"10.1016\/j.jval.2016.03.432"},{"key":"S1047951117000609_ref41","first-page":"723407","article-title":"Respiratory syncytial virus pneumonia treated with lower-dose palivizumab in a heart transplant recipient","volume":"2012","author":"Grodin","year":"2012","journal-title":"Case Rep Cardiol"},{"key":"S1047951117000609_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2010.05.001"},{"key":"S1047951117000609_ref62","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21367"},{"key":"S1047951117000609_ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.1994.tb01207.x"},{"key":"S1047951117000609_ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22826"},{"key":"S1047951117000609_ref58","doi-asserted-by":"publisher","DOI":"10.1017\/S104795110700042X"},{"key":"S1047951117000609_ref22","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","volume":"4","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"S1047951117000609_ref3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0303"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951117000609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T19:32:51Z","timestamp":1659123171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951117000609\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1047951117000609"],"URL":"https:\/\/doi.org\/10.1017\/s1047951117000609","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,16]]},"assertion":[{"value":"\u00a9 Cambridge University Press 2017\u00a0This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}